Literature DB >> 34191790

Myeloid Cell Infiltration Correlates With Prognosis in Cholangiocarcinoma and Varies Based on Tumor Location.

Paul R Kunk1, Sean C Dougherty1, Kevin Lynch2, Rachel Whitehair3, Max Meneveau2, Joseph M Obeid4, Kevin Winters1, Jennifer Y Ju3, Edward B Stelow3, Todd W Bauer2, Craig L Slingluff2, Osama E Rahma5.   

Abstract

Cholangiocarcinoma (CC) is an uncommon malignancy with increasing incidence and dismal prognosis. We conducted a comprehensive analysis of the CC tumor immune microenvironment (TIME) based on tumor location to identify therapeutic targets. We hypothesized that the TIME of CC would vary by primary tumor location and that high tumor infiltration by CD8+ T cells and low infiltration by M2 macrophages would be associated with improved survival. A retrospective analysis was conducted of 99 CC tumor samples surgically resected between 2000 and 2014. Tissue microarrays were constructed from each tumor and stained by immunohistochemistry for 24 markers of immune cells, immune activation or inhibition, programmed cell death-ligand 1, and mesothelin. Most tumors were amply infiltrated with by CD4+, CD8+, and FoxP3+ T cells, as well as by myeloid cells. Mesothelin expression ≥1+ by immunohistochemistry was found in 68% of tumors. We identified higher densities of M1 macrophages in primary distal extrahepatic CC, as well as metastatic lesions. Mesothelin expression was also significantly higher in distal extrahepatic CC. There was no association with survival of infiltration by CD4+, CD8+, or FoxP3+ T cells, mesothelin expression, or programmed cell death-ligand 1 percentage expression, however, high CD14+ myeloid cells and high CD163+ M2 macrophages were associated with worse survival. In conclusion, the CC TIME is a heterogenous milieu highly infiltrated by innate and adaptive immune cells, which differs based on primary tumor location and between primary tumors and metastatic lesions. The correlation of intratumoral M2 macrophages and myeloid cells with a worse prognosis may suggest promising immunotherapeutic targets in CC.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34191790      PMCID: PMC8373662          DOI: 10.1097/CJI.0000000000000378

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.912


  45 in total

Review 1.  Tumour-educated macrophages promote tumour progression and metastasis.

Authors:  Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2004-01       Impact factor: 60.716

2.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).

Authors:  P Argani; C Iacobuzio-Donahue; B Ryu; C Rosty; M Goggins; R E Wilentz; S R Murugesan; S D Leach; E Jaffee; C J Yeo; J L Cameron; S E Kern; R H Hruban
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

3.  Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.

Authors:  Nancy E Thomas; Klaus J Busam; Lynn From; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Alison Venn; Peter A Kanetsky; Pamela A Groben; Honglin Hao; Irene Orlow; Anne S Reiner; Li Luo; Susan Paine; David W Ollila; Homer Wilcox; Colin B Begg; Marianne Berwick
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

4.  Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.

Authors:  Xia Yuan; Jing Zhang; Dan Li; Ye Mao; Fei Mo; Wei Du; Xuelei Ma
Journal:  Gynecol Oncol       Date:  2017-07-08       Impact factor: 5.482

5.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.

Authors:  Christian Steidl; Tang Lee; Sohrab P Shah; Pedro Farinha; Guangming Han; Tarun Nayar; Allen Delaney; Steven J Jones; Javeed Iqbal; Dennis D Weisenburger; Martin A Bast; Andreas Rosenwald; Hans-Konrad Muller-Hermelink; Lisa M Rimsza; Elias Campo; Jan Delabie; Rita M Braziel; James R Cook; Ray R Tubbs; Elaine S Jaffe; Georg Lenz; Joseph M Connors; Louis M Staudt; Wing C Chan; Randy D Gascoyne
Journal:  N Engl J Med       Date:  2010-03-11       Impact factor: 91.245

6.  Immunohistochemical characterization of cancer-associated fibroblasts at the primary sites and in the metastatic lymph nodes of human intrahepatic cholangiocarcinoma.

Authors:  Rei Atono Itou; Naoki Uyama; Seiichi Hirota; Norifumi Kawada; Songtao Wu; Seikan Miyashita; Ikuo Nakamura; Kazuhiro Suzumura; Hideaki Sueoka; Tosihiro Okada; Etsuro Hatano; Hiroko Tsutsui; Jiro Fujimoto
Journal:  Hum Pathol       Date:  2018-08-30       Impact factor: 3.466

7.  Circulating CD14(+) CD16(+) monocyte levels predict tissue invasive character of cholangiocarcinoma.

Authors:  C Subimerb; S Pinlaor; V Lulitanond; N Khuntikeo; S Okada; M S McGrath; S Wongkham
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

8.  In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

Authors:  Franck Pagès; Amos Kirilovsky; Bernhard Mlecnik; Martin Asslaber; Marie Tosolini; Gabriela Bindea; Christine Lagorce; Philippe Wind; Florence Marliot; Patrick Bruneval; Kurt Zatloukal; Zlatko Trajanoski; Anne Berger; Wolf-Herman Fridman; Jérôme Galon
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

9.  Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination.

Authors:  Brian D Robinson; Gabriel L Sica; Yi-Fang Liu; Thomas E Rohan; Frank B Gertler; John S Condeelis; Joan G Jones
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

Review 10.  Immunobiology of cholangiocarcinoma.

Authors:  Emilien Loeuillard; Caitlin B Conboy; Gregory J Gores; Sumera Rizvi
Journal:  JHEP Rep       Date:  2019-07-10
View more
  3 in total

1.  Drivers and breaks in the cholangiocarcinoma immune microenvironment.

Authors:  Caitlin B Conboy; Sumera I Ilyas; Gregory J Gores
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 8.265

Review 2.  The Role of Metabolic Plasticity of Tumor-Associated Macrophages in Shaping the Tumor Microenvironment Immunity.

Authors:  Md Nabiul Hasan; Okan Capuk; Shivani M Patel; Dandan Sun
Journal:  Cancers (Basel)       Date:  2022-07-08       Impact factor: 6.575

Review 3.  Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.

Authors:  Hengsong Cao; Tian Huang; Mingrui Dai; Xiangyi Kong; Hanyuan Liu; Zhiying Zheng; Guoqiang Sun; Guangshun Sun; Dawei Rong; Zehua Jin; Weiwei Tang; Yongxiang Xia
Journal:  Int J Biol Sci       Date:  2022-08-21       Impact factor: 10.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.